ATE83925T1 - Dosisformen mit definiertem wassergehalt zur gesteuerten freigabe. - Google Patents

Dosisformen mit definiertem wassergehalt zur gesteuerten freigabe.

Info

Publication number
ATE83925T1
ATE83925T1 AT89305209T AT89305209T ATE83925T1 AT E83925 T1 ATE83925 T1 AT E83925T1 AT 89305209 T AT89305209 T AT 89305209T AT 89305209 T AT89305209 T AT 89305209T AT E83925 T1 ATE83925 T1 AT E83925T1
Authority
AT
Austria
Prior art keywords
controlled release
water content
dosage forms
defined water
dosage form
Prior art date
Application number
AT89305209T
Other languages
English (en)
Inventor
Joanne Heafield
Stewart Thomas Leslie
Sandra Therese Antoi Malkowska
Philip John Neale
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of ATE83925T1 publication Critical patent/ATE83925T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT89305209T 1988-06-02 1989-05-23 Dosisformen mit definiertem wassergehalt zur gesteuerten freigabe. ATE83925T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB888813064A GB8813064D0 (en) 1988-06-02 1988-06-02 Controlled release dosage forms having defined water content
EP89305209A EP0344960B1 (de) 1988-06-02 1989-05-23 Dosisformen mit definiertem Wassergehalt zur gesteuerten Freigabe

Publications (1)

Publication Number Publication Date
ATE83925T1 true ATE83925T1 (de) 1993-01-15

Family

ID=10637952

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89305209T ATE83925T1 (de) 1988-06-02 1989-05-23 Dosisformen mit definiertem wassergehalt zur gesteuerten freigabe.

Country Status (19)

Country Link
US (1) US5091189A (de)
EP (1) EP0344960B1 (de)
JP (1) JPH0816060B2 (de)
KR (1) KR0136279B1 (de)
AT (1) ATE83925T1 (de)
AU (1) AU610401B2 (de)
CA (1) CA1323834C (de)
DE (1) DE68904119T2 (de)
DK (1) DK175130B1 (de)
ES (1) ES2053989T3 (de)
FI (1) FI93695C (de)
GB (2) GB8813064D0 (de)
GR (1) GR3007088T3 (de)
IE (1) IE61998B1 (de)
IL (1) IL90462A (de)
NO (1) NO176232C (de)
NZ (1) NZ229372A (de)
PT (1) PT90722B (de)
ZA (1) ZA894201B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262115B1 (en) * 1995-05-22 2001-07-17 Alza Coporation Method for the management of incontinence
US5912268A (en) * 1995-05-22 1999-06-15 Alza Corporation Dosage form and method for treating incontinence
CA2314896C (en) * 1997-12-22 2005-09-13 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
JP2001526228A (ja) 1997-12-22 2001-12-18 ユーロ−セルティーク，エス．エイ． オピオイド作動薬／拮抗薬の併用
AU1738800A (en) 1998-11-23 2000-06-13 Bonnie Davis Dosage formulations for acetylcholinesterase inhibitors
HU229705B1 (en) 2000-02-08 2014-05-28 Euro Celtique Sa Tamper-resistant oral opioid agonist formulations
CN1525851A (zh) 2001-05-11 2004-09-01 ������ҩ�����޹�˾ 抗滥用阿片样物质控释剂型
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
SI1416842T1 (sl) * 2001-07-18 2009-06-30 Euro Celtique Sa Farmacevtske kombinacije oksikodona in naloksona
ATE431738T1 (de) 2001-08-06 2009-06-15 Euro Celtique Sa Opioid-agonist-formulierungen mit freisetzbarem und sequestriertem antagonist
AU2002324624A1 (en) 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
IN192180B (de) * 2001-09-28 2004-03-06 Ranbaxy Lab
CA2479350A1 (en) * 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
EP1492505B1 (de) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmazeutische zubereitung enthaltend oxycodon und naloxon
US7815934B2 (en) 2002-09-20 2010-10-19 Alpharma Pharmaceuticals, Llc Sequestering subunit and related compositions and methods
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
WO2004067039A1 (en) * 2003-01-28 2004-08-12 Collegium Pharmaceutical, Inc. Multiparticulate compositions of milnacipran for oral administration
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1604666A1 (de) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit
ES2317313T3 (es) * 2004-10-19 2009-04-16 Krka, Tovarna Zdravil, D.D., Novo Mesto Composicion farmaceutica solida que comprende clorhidrato de donepezilo.
EP1702558A1 (de) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Verfahren und Vorrichtung zur Darmtätigkeitserfassung
EP1942875B1 (de) * 2005-08-24 2015-08-12 Rubicon Research Private Limited Formulierung mit kontrollierter freisetzung
SI2719378T1 (sl) 2006-06-19 2016-11-30 Alpharma Pharmaceuticals Llc Farmacevtski sestavki
PL2068816T3 (pl) * 2006-09-29 2018-03-30 The Procter And Gamble Company Kompozycje do higieny jamy ustnej zawierające sieci żelowe
EP2224808A4 (de) * 2007-12-17 2013-11-27 Alpharma Pharmaceuticals Llc Pharmazeutische zusammensetzung
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
RU2478388C2 (ru) * 2008-07-07 2013-04-10 Еуро-Селтик С.А. Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
CN114053235B (zh) * 2020-08-07 2023-07-18 广州白云山光华制药股份有限公司 茶碱缓释片及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
US4743247A (en) * 1984-08-13 1988-05-10 Alza Corporation Process for manufacturing dosage form
US4753800A (en) * 1985-10-04 1988-06-28 Warner-Lambert Company Medicament adsorbates and their preparation
US4892742A (en) * 1985-11-18 1990-01-09 Hoffmann-La Roche Inc. Controlled release compositions with zero order release
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
DE3750145T2 (de) * 1986-06-10 1994-11-03 Euro Celtique Sa Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
GB8628728D0 (en) * 1986-12-02 1987-01-07 Euro Celtique Sa Spheroids

Also Published As

Publication number Publication date
IE891744L (en) 1989-12-02
ZA894201B (en) 1990-03-28
GR3007088T3 (de) 1993-07-30
DE68904119T2 (de) 1993-06-09
IL90462A0 (en) 1990-01-18
FI93695C (fi) 1995-05-26
KR900000077A (ko) 1990-01-30
DE68904119D1 (de) 1993-02-11
DK175130B1 (da) 2004-06-14
GB8813064D0 (en) 1988-07-06
JPH0225420A (ja) 1990-01-26
JPH0816060B2 (ja) 1996-02-21
AU610401B2 (en) 1991-05-16
NO176232B (no) 1994-11-21
NO176232C (no) 1995-03-01
ES2053989T3 (es) 1994-08-01
EP0344960A2 (de) 1989-12-06
DK266889D0 (da) 1989-06-01
IE61998B1 (en) 1994-12-14
FI93695B (fi) 1995-02-15
FI892664L (fi) 1989-12-03
GB2219207B (en) 1992-01-02
GB8911629D0 (en) 1989-07-05
EP0344960B1 (de) 1992-12-30
NO892229D0 (no) 1989-06-01
IL90462A (en) 1993-01-31
PT90722B (pt) 1994-11-30
US5091189A (en) 1992-02-25
FI892664A0 (fi) 1989-06-01
NZ229372A (en) 1991-07-26
KR0136279B1 (ko) 1998-04-25
AU3512789A (en) 1989-12-07
NO892229L (no) 1989-12-04
EP0344960A3 (en) 1990-03-07
DK266889A (da) 1989-12-03
PT90722A (pt) 1989-12-29
CA1323834C (en) 1993-11-02
GB2219207A (en) 1989-12-06

Similar Documents

Publication Publication Date Title
ATE83925T1 (de) Dosisformen mit definiertem wassergehalt zur gesteuerten freigabe.
ATE65386T1 (de) Verwendung von poroesen fuellstoffen in polymerisierbaren dentalmassen, solche massen und deren verwendung zur herstellung von formkoerpern.
FR2646673B1 (fr) Silice sous forme de bille, procede de preparation et son utilisation au renforcement des elastomeres
AU562938B2 (en) 7, 10, 13, 16 docosatetraenoic acid composition
GB8620484D0 (en) Plugged microporous film
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
IT1215332B (it) Composizione farmaceutica contenente sulglicotide per la terapia dell'ulcera gastrica
FI871116A0 (fi) Kontrollerbart frigoerande nifedipinprodukter.
DK0381220T3 (da) Vanddispergerbart gemfibrozilpræparat
ZA885372B (en) Nutrieut mixture intended for the elderly
FR2518881B1 (fr) Medicaments a base de 26,23-lactones de la 25-hydroxyvitamine d3, utiles notamment pour agir sur la concentration en calcium du serum
FR2578866B1 (fr) Procede pour reguler, dans le but d'effectuer le brulage dans le four a carbonate de soude, les conditions d'alimentation ou de combustion de lessives usees concentrees de compositions physiques et chimiques variees.
FR2582909B1 (fr) Produit pour l'alimentation des ruminants et sa preparation.
IT8882523A0 (it) Metodo per l'avanzamento del piede particolarmente nei pedali per velocipedi.
ATA188385A (de) Verwendung von peroxydiphosphaten zur herstellung von pharmazeutischen tabletten bzw. pharmazeutischen waesserigen loesungen
Eady The onset of language specific patterning in infant vocalization.
PT87804A (pt) Nacelle inclinable ou reversible notamment pour voiture d'enfant
ES2052701T3 (es) Agente hipouricemico que contiene ponalrestat.
EP0143886A3 (en) Humidifier
JPS5288576A (en) Treatment of chlorella cultivation waste liquid
ATE5723T1 (de) Substituierte pyrazinyl-1,2,4-oxadiazole, verfahren zur herstellung derselben und eine dieselben enthaltende pharmazeutische zubereitung.
JPS5372371A (en) Fluidic control system

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time